SITC Archive Library

The Society for Immunotherapy of Cancer (SITC) hosted the 2018 Immuno-Oncology Biomarkers: State of the Art on May 16-17, 2018. Available here are the presentation slides and video from Session I: State of the Art.

Program Committee

• Chair: Lisa H. Butterfield, PhD – University of Pittsburgh
• Mary L. Disis, MD, FACP – University of Washington
• Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Robert W. Franz Cancer Center
• David Kaufman, MD, PhD – Bill & Melinda Gates Medical Center
• Samir N. Khlief, MD – Georgetown University
• Ena Wang, MD – AbbVie Biotherapeutics Corp.

• Stacey Adam, PhD – Foundation for the National Institutes of Health
• Helen Chen, MD – National Cancer Institute

The Immuno-Oncology Biomarkers Workshop will identify the next steps for action in immunotherapy biomarker development. It will provide a forum for energetic discussion about the collaborative efforts across several societies and consortia, make progress on identification and analysis of novel biomarkers, and tackle data analysis and specimen sharing. The final session will bring together representatives from the fields of immune-oncology research, infectious disease, autoimmune disease and cell biology to discuss opportunities for cross-disciplinary collaboration to advance biomarker development.

Panel discussions following each didactic presentation will allow all participants to contribute to the conversation, and to shape the innovative collaborations, next projects and other outputs that the SITC Immune Biomarkers Committee will incorporate over the next several years.

Intended Audience

The target audience for this program includes a broad representation from academia, biotech, pharma, government, researchers and early career individuals who wish to understand the biomarkers state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.